ImmunOs Therapeutics raises $11 million and further strengthens investor base

“ImmunOs Therapeutics has a very innovative approach to target myeloid checkpoints which are potentially the next major breakthrough in immuno-oncology”

24-Sep-2024 - ImmunOs Therapeutics AG, a biopharmaceutical company leveraging its unique immune system modulating HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, announced the closing of a Series C financing round of $11 million. The ...

APEIRON Biologics to be Acquired by Ligand Pharmaceuticals for USD 100 Million

Ligand also commits to invest up to USD 4 million in APEIRON spin-off, invIOs

10-Jul-2024 - APEIRON Biologics AG announced that its shareholders have entered into a definitive agreement to sell their APEIRON shares to US-based Ligand Pharmaceuticals Incorporated for USD 100 million. APEIRON shareholders are also entitled to additional consideration based on future commercial and ...

Exeliom Biosciences Announces Series A Extension and Final Closing with Total of €24 Million

Funding to advance clinical development of its lead candidate in immuno-oncology and infectious diseases

05-Jul-2023 - Exeliom Biosciences (formerly Nextbiotix), a clinical-stage biopharmaceutical company leveraging its unique knowledge of the microbiome-immunomodulation axis to develop next-generation immunotherapies, announced the completion of its €24 million ($26 million) Series A with a last extension of €8 ...

NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures

Advance Novel Immuno-Oncology Programs

12-Jan-2023 - NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. The ...

BioNTech and Ryvu Therapeutics enter partnership

Research collaboration for several small molecule immunotherapy programs

02-Dec-2022 - BioNTech SE and Ryvu Therapeutics S.A., a clinical-stage company developing oncology therapeutics announced that the companies have entered into a multi-target research collaboration for several small molecule immunotherapy programs as well as an exclusive license agreement for Ryvu’s STING ...

invIOs goes live with unique cell therapy platform and clinical-stage immuno-oncology pipeline

23-Dec-2021 - invIOs (innovative Immuno-Oncology) GmbH, a privately held biotechnology company developing novel therapies for cancer, is pleased to announce it will commence operations on 1 January 2022. invIOs, a fully owned subsidiary of APEIRON Biologics AG has been assigned APEIRON’s innovative cancer ...

Sanofi to acquire Amunix immuno-oncology pipeline with next generation Conditionally Activated Biologics

22-Dec-2021 - Sanofi announced that it has entered into an agreement to acquireAmunix Pharmaceuticals, Inc., an immuno-oncology company leveraging its proprietary, clinically validatedXTEN® and innovative universal protease-releasable masking technology platform, Pro-XTENTM, to discover and develop ...

€12M Series A Financing to Develop Novel Immuno-Virotherapies Against Cancer

17-Oct-2019 - Abalos Therapeutics announced a EUR 12 million Series A financing round establishing its operations and leadership. The Company’s objective is to develop new immuno-oncology therapeutics based on a specific arenavirus strain that preferentially infects and proliferates in cancer cells generating ...

Boehringer Ingelheim acquires swiss biotech start-up

17-Jul-2019 - Boehringer Ingelheim announced its acquisition of all shares of AMAL Therapeutics SA, a private Swiss biotechnology company focused on cancer immunotherapy and advancing first in class therapeutic cancer vaccines derived from its technology platform KISIMA. AMAL’s lead vaccine ATP128 is currently ...

MorphoSys and Vivoryon Therapeutics Enter Agreement in Immuno-Oncology

10-Jul-2019 - MorphoSys AG and Vivoryon Therapeutics AG announced that they have entered into an agreement under the terms of which MorphoSys has obtained an exclusive option to license Vivoryon's small molecule QPCTL inhibitors in the field of oncology. The option covers worldwide development and ...